Nonsurgical Treatments for Torn Rotator Cuff | NYU Langone Health
NYU Langone doctors may manage a torn rotator cuff with nonsurgical approaches, such as activity modification and physical therapy.
Nontuberculous Mycobacteria Patient Education Program Registration Form | NYU Langone Health
Use our online form to register for NYU Langone's 2017 Nontuberculous Mycobacterial Patient Education Program.
Nontuberculous Mycobacterial Infections | NYU Langone Health
NYU Langone doctors identify and treat nontuberculous mycobacterial infections.
Normal Pressure Hydrocephalus | NYU Langone Health
NYU Langone doctors offer treatment plans to restore independence in people who have normal pressure hydrocephalus, or spinal fluid in the brain.
Notice of Change Healthcare Security Incident | NYU Langone Health
NYU Langone Health is making public notice of a Change Healthcare security incident.
Notice of Privacy Practices | NYU Langone Health
NYU Langone’s Notice of Privacy Practices describes how medical information about you may be used and disclosed, and how to get access to it.
Novel Coding Strategies for Children with Cochlear Implants
Prior to the onset of deafness, the auditory brain of post-lingually deafened adults develops in response to a rich complement of spectral, temporal, and intensity cues from acoustic input. After becoming deaf and subsequently receiving a cochlear implant (CI), these recipients need time to adjust to the CI but eventually attain relatively high levels of speech understanding. By contrast, the auditory brain of children who are born deaf and receive a CI develops in direct response to electrical stimulation. Although their auditory systems do not benefit from the same rich acoustic input as that of post-lingually deafened adults prior to deafness, children have the advantage of adapting to the CI during the time window when neural plasticity is most sensitive. Therefore, it is assumed that the auditory brains of these two populations are different—yet both groups are fitted with the same coding strategies that were developed primarily for post-lingually deafened adults without consideration of children’s select listening needs. Although many implanted children do develop speech recognition (e.g. Niparko et al., 2010; Eisenberg et al., 2016) outcome variability remains high. Evidence from a small group of children with single-channel CIs (Berliner et al., 1989) suggests that early deafened children are able to access temporal cues from electrical stimulaton to understand speech in an open set. Pilot data from the Landsberger lab suggest that children with multichannel CIs attain better modulation detection thresholds than adult CI recipients. We recently published that early deafened children are less able to access spectral cues from multichannel CIs to the same extent as post-lingually deafened adults and hearing children (Landsberger et al., 2017). Taken together, these findings imply that early implanted children develop auditory skills differently than implanted adults through differential weighting of cues or combinations of cues. If so, then establishing optimal CI programming strategies, such as adjusting amplitude mapping to maintain key spectro-temporal contrasts, could conceivably improve perceptual outcomes for early implanted children.
Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients with Breast Cancer at High Risk of Recurrence
Scientific Rationale for the study design: Copper depletion is designed to be a complement to standard therapy to overcome resistance mechanisms hence it would be optimal to combine it with standard adjuvant therapy which at the current time is capecitabine and pembrolizumab.Study Design:Phase 1b: Patients with triple negative breast cancer who have completed standard neoadjuvant therapy (chemotherapy + pembrolizumab) and who have residual disease at RCB 2, 3 will start adjuvant therapy with standard dose capecitabine, standard dose pembrolizumab and tetrathiomolybdate (TM). Patients must have received neoadjuvant immunotherapy (pembrolizumab) and wish to continue adjuvant immunotherapy for at least one cycle on trial. The capecitabine will be for 6 months with concurrent TM and TM will continue for an additional 2.5 years (for a total of 3 years of treatment). Patients must stay on immunotherapy for at least the first cycle of the study and subsequently as per physician's choice.This phase of the study is designed to assess safety of TM with capecitabine + immunotherapy (pembrolizumab) as adjuvant therapy for TNBC.With a standard 3+3 design, the maximum possible total number of patients is 18.Randomized Phase 2: Patients with triple negative breast cancer who have completed standard neoadjuvant therapy (chemotherapy +/- pembrolizumab) and who have residual disease at RCB 2, 3 will start adjuvant therapy with standard dose capecitabine or capecitabine and tetrathiomolybdate (TM). If they received neoadjuvant pembrolizumab and wish to continue adjuvant immunotherapy, they may continue. The capecitabine will be for 6 months with concurrent TM and TM will continue for an additional 2.5 years (for a total of 3 years of treatment). If they elect to continue immunotherapy, then they should complete one year total or as per physician's choice.Patients will be randomized with a 1:1 allocation ratio between the two treatment arms.There will be at most 186 patients accrued to account for 10% loss to follow-up over the course of the approximately 5-year study period.
Novelty and Early Assessment of Temperament (NEAT) Study
This pilot study will examine individual differences in how the brain processes novelty. This will provide preliminary data on the neural mechanisms that underlie attention to novelty, a key behavioral risk marker of anxiety disorders.
NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I HORMONE SENSITIVE HER2-NEGATIVE ONCOTYPE RECURRENCE SCORE = 18 BREAST CANCER
Primary ObjectiveTo evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of ipsilateral-breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.Primary HypothesisBreast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral-breast tumor recurrence (IBTR) as compared to breast conservation, breast radiation, and endocrine therapy.